Hypothesis

Transient expression of OSK factors reverses epigenetic age more effectively when cellular NAD+ levels are elevated, because NAD+-dependent TET enzyme activity drives the DNA demethylation required for clock reset without triggering pluripotency.

Mechanistic Rationale

• OSK-induced chromatin opening creates substrates for TET-mediated hydroxylation of 5-methylcytosine.
• TET enzymes require NAD+ as a cofactor for optimal activity; low NAD+ in aged tissues limits demethylation speed and completeness.
• Raising NAD+ with precursors such as nicotinamide riboside (NR) should increase TET flux, allowing shorter or lower‑dose OSK pulses to achieve the same epigenetic rejuvenation.
• This mechanism predicts tissue‑specific differences in OSK response that correlate with baseline NAD+ abundance.

Predictions

1. In aged mice, cyclic OSK plus NR will reduce epigenetic age (measured by multi‑tissue DNAm clocks) to a greater extent than OSK alone after matched exposure duration.
2. The improvement will be strongest in tissues with initially low NAD+ (e.g., liver, kidney) and modest in high‑NAD+ tissues (e.g., brain, heart).
3. No increase in pluripotency marker expression or tumorigenic incidence will be observed when NAD+ is boosted, indicating that identity preservation is maintained.
4. If NAD+ supplementation fails to augment OSK‑mediated demethylation, the hypothesis is falsified.

Experimental Design

• Animals: 20‑month‑old C57BL/6 mice, both sexes, n=10 per group.
• Groups: (a) vehicle control, (b) OSK pulses only (AAV‑OSK, doxycycline 2 days on/5 days off for 4 weeks), (c) NR only (400 mg/kg/day in diet), (d) OSK + NR (same OSK regimen with NR supplementation).
• Readouts (collected at baseline, post‑treatment, and 4‑week washout):
  • Multi‑tissue epigenetic clocks (liver, lung, heart, brain, blood).
  • Tissue‑specific functional assays (ALT/AST for liver, lung compliance, echocardiogram, cognitive maze).
  • Pluripotency markers (OCT4, NANOG) by immunostaining and qPCR.
  • Tumor surveillance (necropsy, histology).
  • NAD+ metabolomics to confirm target engagement.
• Statistical plan: Two‑way ANOVA with factors OSK and NR, post‑hoc Tukey; significance set at p<0.05.

Potential Outcomes and Interpretation

• Synergistic rejuvenation: OSK + NR shows a >15 % greater reduction in epigenetic age versus OSK alone, with functional gains matching or exceeding those seen in prior OSK‑only studies. This would support NAD+ as a rate‑limiting cofactor for TET activity during reprogramming.
• Additive or no effect: No significant difference between OSK and OSK + NR groups. This would refute the NAD+‑dependent TET model and suggest other bottlenecks (e.g., chromatin accessibility, histone modifications) dominate the resetting process.
• Safety concerns: Any rise in pluripotency markers or tumor formation would indicate that NAD+ elevation pushes OSK toward excessive dedifferentiation, refining the safety window for combined interventions.

This hypothesis is directly testable, leverages existing delivery tools, and links a readily modulatable metabolic pathway to the mechanistic core of epigenetic rejuvenation.